https://doi.org/10.55788/cd39f635
In the CONFIRM trial, 300 participants with type 1 HRS and cirrhosis, demonstrating rapid progressive renal failure, were randomised to receive either terlipressin or placebo [1]. Notably, the study included those with suspected or confirmed alcoholic hepatitis, a condition that exacerbates the already high mortality risk of HRS.
Alcoholic hepatitis was identified in around 40% of the participants at baseline in both the terlipressin and placebo groups. Among this population subgroup, terlipressin proved significantly superior in achieving the trial's primary endpoint, the verified reversal of HRS. Terlipressin showed a success rate of HRS reversal of 30.9%, compared with 7.7% for the placebo (P=0.005). Rates of renal replacement therapy by day 30 were slightly lower in the terlipressin group (21%) compared with the placebo group (25.6%), albeit not statistically significant (P=0.568).
While rates of intensive care unit (ICU) admission were similar between the subgroups, the terlipressin-treated participants had a shorter average ICU length of stay (6.9 days vs 12.4 days; P=0.514). Transplant-free survival was also numerically higher in the terlipressin group, with a median of 28 days versus 15 days in the placebo group, although the difference was not statistically significant (P=0.207).
In summary, these findings suggest that terlipressin treatment is associated with higher rates of verified HRS reversal in participants with concomitant alcoholic hepatitis, with a trend towards lower rates of renal replacement therapy and shorter ICU stays. "This data strongly supports a role for terlipressin for those with type 1 HRS and alcohol-associated hepatitis," Dr Kevin Korenblat (Washington University School of Medicine, MO, USA) said. Despite the promising results, further research is needed to definitively establish the potential benefits of terlipressin in this patient subgroup.
- Korenblat K, et al. Clinical responses to terlipressin in the subgroup of patients with hepatorenal syndrome further compounded by alcoholic hepatitis: analysis of the CONFIRM phase III study. Lecture 651, DDW 2023, 6–9 May, Chicago, IL, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Mepolizumab shows potential in eosinophilic oesophagitis treatment Next Article
Effectiveness of B/F/TAF treatment in HIV/HBV co-infection »
« Mepolizumab shows potential in eosinophilic oesophagitis treatment Next Article
Effectiveness of B/F/TAF treatment in HIV/HBV co-infection »
Table of Contents: DDW 2023
Featured articles
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
Upper GI Disorders: Hot Topics
Dupilumab improves eosinophilic oesophagitis outcomes, regardless of history of oesophageal dilation
Inflammatory Bowel Disease: Novel Developments
EVOLVE Expansion study: vedolizumab and ustekinumab as first-line biologic treatments for Crohn’s disease
Environmental and dietary factors can amplify paediatric IBD risk
Ulcerative colitis: bowel urgency remission associated with improvement in fatigue
Crohn’s disease: Upadacitinib improves endoscopic outcomes in participants with or without previous biologic failure
Microbiota in GI Diseases
Durability of SER-109 clinical response in patients with recurrent Clostridioides difficile infection
IBS management: the complex role of dietary fibres
Daily and seasonal fluctuations in the gut microbiome
Spotlight on Colorectal Cancer
Colorectal cancer: Aspirin and NSAIDs could reduce the risk of early-onset adenomas
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
What is New in Hepatology?
Terlipressin shows promise for participants with hepatorenal syndrome and concomitant alcoholic hepatitis
Related Articles
October 23, 2019
β-blockers may halt cirrhosis progression: PREDESCI trial
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy